News

Back

Stealth BioTherapeutics to Present at Cowen & Co. 36th Annual Health Care Conference

March 01, 2016

BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Cowen & Co. 36th Annual Health Care Conference at 12:00 p.m. ET on Tuesday, March 8, 2016 in Boston.

Stealth BioTherapeutics: Leading Mitochondrial Medicine
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. Stealth’s clinical development program is focused along several core therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases.  More information regarding Stealth and its pipeline is available at StealthBT.com.


Contact:

Media Relations
dna Communications
Taylor Ramsey
Phone: (617) 520-7018
Media@StealthBT.com

Investor Relations
Stern IR
Beth DelGiacco
Phone: (212) 362-1200
IR@StealthBT.com

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com